Vorgun-Rapid 0.3/0.5 – Voglibose & Repaglinide Tablets IP – 1 × 10 Tablets

Vorgun-Rapid 0.3/0.5 Tablets offer a premium, clinically integrated combination therapy meticulously engineered for the targeted management of postprandial hyperglycemia (sudden blood sugar spikes after eating) in adult patients with Type 2 Diabetes Mellitus. By blending a rapid-acting insulin secretagogue with a localized intestinal enzyme inhibitor into a single daily unit, this formulation delivers comprehensive, synchronized glycemic control right at the source of meal consumption. This specific 0.3 mg / 0.5 mg strength ratio is ideal for patients who require standard carbohydrate delay but need a lower, gentler dose of repaglinide to balance baseline therapy goals.

The first active component, Repaglinide (0.5 mg), belongs to the meglitinide (glinide) class of fast-acting prandial glucose regulators. It functions by closing ATP-dependent potassium ($K_{\text{ATP}}$) channels in the pancreatic beta-cell membranes. This blockade depolarizes the cell, opening voltage-gated calcium channels, which triggers a rapid, burst-like release of insulin that precisely matches the incoming meal load. Because of its highly short physiological profile, it clears quickly, minimizing the risk of prolonged low blood sugar. The second component, Voglibose (0.3 mg), acts as a competitive alpha-glucosidase inhibitor in the small intestine. It selectively blocks enzymes responsible for breaking complex oligosaccharides and disaccharides into simple absorbable monosaccharides. By delaying carbohydrate breakdown and stretching out glucose absorption, Vorgun-Rapid 0.3/0.5 smoothly levels out mealtime glucose peaks, safeguarding vascular linings and improving long-term metabolic health tracking.

Key Benefits

• Advanced Mealtime Glycemic Control: Dual mechanism directly flattens high post-meal sugar peaks, reducing cardiovascular strain.

• Rapid-Burst Insulin Release: Repaglinide activates immediate, physiological insulin deployment to handle carbohydrates efficiently.

• Delayed Sugar Absorption: Voglibose stretches out intestinal carbohydrate breakdown, preventing sharp glucose rushes into circulation.

• Gentler Glinide Baseline: The 0.5 mg repaglinide configuration offers an optimal solution for patients requiring milder baseline insulin adjustment or precise titration tracking.

• Low Risk of Fasting Hypoglycemia: Fast-acting, short-duration active pathways ensure medicine clears rapidly once the meal phase concludes.

• Trusted Quality: Manufactured under the strict pharmaceutical parameters of Daxia Healthcare, ensuring exact dosing uniformity and target bio-availability.

Directions for Use

• Take exactly as directed by your endocrinologist or primary physician.

• Swallow the tablet whole with a full glass of water. Do not crush, break, or chew it.

• Vorgun-Rapid 0.3/0.5 must strictly be taken orally within 15 to 30 minutes BEFORE starting each major meal (such as breakfast, lunch, or dinner).

• Crucial Guideline: If a meal is skipped or missed from your schedule, the corresponding dose of this medication must also be omitted to prevent low blood sugar tracking issues.

Safety & Precautions

• Do not modify your dose or stop taking this medication suddenly. Abruptly halting antidiabetic therapy can cause blood glucose trends to bounce back sharply, leading to severe metabolic imbalances.

• Risk of Hypoglycemia (Low Blood Sugar): While the 0.5 mg repaglinide component is a lower dose, this combination can still cause low blood sugar if food intake is delayed or insufficient. If hypoglycemia occurs, you must treat it with pure glucose (dextrose) or honey, NOT standard table sugar (sucrose). The voglibose component blocks the breakdown of common table sugar, which will prevent it from raising your blood glucose quickly in an emergency.

• Because this medicine delays carbohydrate digestion in the gut, it may cause initial mild flatulence, bloating, or soft stools during the first few weeks of therapy layout.

• Contraindicated for individuals with Type 1 Diabetes, diabetic ketoacidosis, severe liver or kidney failure, or severe gastrointestinal disorders/obstructions.

• Keep out of reach of children.

Storage

• Store in a cool, dry place below 30°C.

• Protect from direct sunlight, excessive heat, and environmental room moisture.

• Keep the tablets safely stored inside their original protective packaging configuration until the exact moment of consumption.